Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection Part 1: Cognitive functioning
Whiteside, Douglas M. , Basso, Michael R. , Naini, Savana M. , Porter, James N., Holker, Erin , Waldron, Eric J. , Melnik, Tanya E., Niskanen, Natalie, Whiteside, Douglas , Taylor, Sarah E.

Mayo Clinic

The Clinical Neuropsychologist | February 8, 2022 | Volume: 36 | Issue: 4 | Pages: 806-828

10.1080/13854046.2022.2030412 | PMID 35130818 Get It

An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
HaDuong, Josephine H. , Heske, Christine M. , Allen‐Rhoades, Wendy , Xue, Wei , Teot, Lisa A., Rodeberg, David A. , Donaldson, Sarah S. , Hawkins, Douglas S. , Venkatramani, Rajkumar , Hawkins, Douglas S , Rodeberg, David A , Donaldson, Sarah S , Allen-Rhoades, Wendy A , Weiss, Aaron R.

Mayo Clinic

Pediatric Blood & Cancer | February 7, 2022 | Volume: 69 | Issue: 4 | Pages: No page available

10.1002/pbc.29511 | PMID 35129294 Get It

AbstractChildren and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous population with variable overall survival rates ranging between approximately 6% and 100% depending on defined risk factors. Although the risk stratification of patients has been refined across five decades of collaborative group studies, molecular prognostic biomarkers beyond FOXO1 fusion status have yet to be incorporated prospectively in upfront risk‐based therapy assignments. This review describes the evolution of risk‐based therapy and the current risk stratification, defines a new risk stratification incorporating novel biomarkers, and provides the rationale for the current and upcoming Children's Oncology Group RMS studies.
The incidence of torsades de pointes with peri‐operative low‐dose ondansetron administration
Nuttall, Gregory A. , Voogd, Sarah C., Danke, Heather, Warner, Paul A., Oyen, Lance J., Marienau, Mary Shirk, Ackerman, Michael J.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | February 6, 2022 | Volume: 42 | Issue: 4 | Pages: 292-297

10.1002/phar.2668 | PMID 35124842 Get It

AbstractStudy ObjectiveThe primary objective of this retrospective safety study was to determine the incidence of torsades de pointes (TdP) or death following perioperative administration of low‐dose, 4 mg, ondansetron for postoperative nausea and vomiting.Design and SettingThis is a single‐center retrospective clinical trial.PatientsThe authors identified 32,737 patients who received 37,589 doses of ondansetron during a 2‐year time frame between March 2009 and February 2011 for surgical nausea prophylaxis or treatment of nausea.Measurements and Main ResultsPatients were cross‐matched with an electrocardiogram and adverse outcome database; this identified 4759 patients with documentation of a QTc >450 milliseconds (ms), all ventricular tachycardias including TdP within 48 hours of receiving ondansetron, or death within 7 days of receiving ondansetron. No patients developed TdP or died as a direct result of ondansetron administration (n = 0; event rate = 0.0 per 10,000, 95% CI 0.0 to 1.1 per 10,000). Forty‐six of 32,737 surgical patients had documented monomorphic ventricular tachycardia (VT) (n = 14; event rate = 4.3 per 10,000, 95% CI 2.3 to 7.2 per 10,000) or died (n = 32; event rate = 9.8 per 10,000, 95% CI 6.7 to 13.8 per 10,000) within 48 h of ondansetron administration. All monomorphic VT episodes were precipitated by existing cardiovascular disease; and 7 of 14 patients had documented monomorphic VT prior to receiving ondansetron. Of the 32 surgical patients who died, all deaths were precipitated by pre‐existing disease.ConclusionNo episodes of TdP were identified in patients receiving ondansetron perioperatively. This suggests that low‐dose ondansetron does not contribute to the development of TdP.
Developing biomarkers of TDP‐43‐related splicing dysfunction in frontotemporal dementia
Qi, Andy, Hawrot, James , Coon, Steven L. , Petrucelli, Leonard , Seddighi, Sahba , Hill, Sarah E. , Brown, Anna‐Leigh , Qi, Andy, Fratta, Pietro , Ward, Michael E.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.055170 Get It

AbstractBackgroundFrontotemporal dementia (FTD) is a rapidly progressive neurodegenerative disorder characterized by prominent atrophy of the frontal and temporal lobes and marked language and/or behavioral disturbances. Mislocalization of the TAR DNA‐binding protein 43 (TDP‐43) – characterized by both its nuclear loss and its cytosolic accumulation – occurs in up to 50% of FTD cases. Recent evidence from our group and others demonstrates that loss of TDP‐43‐dependent splicing activity occurs in FTD patient brains, is an early disease phenomenon, and contributes directly to neuronal death. Monitoring the products of TDP‐43 related mis‐splicing may, thus, yield promising biomarker candidates of early cellular dysfunction in FTD.MethodWe propose a series of proteogenomic studies in human iPSC neurons, post‐mortem brain, and patient biospecimens to identify and develop protein‐based biomarkers of RNA mis‐splicing in FTD. First, we will identify pathologic RNA splicing changes and protein products of mis‐splicing that occur in the context of TDP‐43 depletion in iPSC‐derived neurons. We will next determine which of these predicted transcripts and de novo proteins occur in post‐mortem human FTD brains, as a crucial first step in biomarker development. Finally, we will develop CSF biomarkers of FTD‐related mis‐splicing through a combination of targeted proteomics and ELISA‐based assays of lead candidate biomarkers.ResultUsing CRISPRi knockdown of TDP‐43 in i3Neurons followed by total RNAseq, we detected cryptic exon formation in STMN2 as well as hundreds of additional transcripts. We developed a proteogenomic informatic pipeline to detect de novo protein products of mis‐spliced transcripts in TDP‐43 deficient i3Neurons, revealing two in‐frame de novo peptides in the MYO18A transcript. Furthermore, we detected 38 of these mis‐spliced transcripts in ALS/FTD post‐mortem cortex, including MYO18A.ConclusionThese preliminary studies indicate that our i3Neuron CRISPRi pipeline can predict disease‐relevant markers of TDP‐43 mis‐splicing and suggest a proteogenomic workflow for development of novel protein‐based biomarkers of mis‐spliced transcripts.Together, these efforts will yield early biomarkers of TDP‐43 related cellular dysfunction that can act as surrogate measures of disease onset and progression in FTD.
The location of PSEN1 pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study
Fitzpatrick, Colleen , Chui, Helena C., Fagan, Anne M. , Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Johnson, Keith A., Chhatwal, Jasmeer P. , DIAN, Schultz, Stephanie A. , Schultz, Aaron P. , Joseph‐Mathurin, Nelly , McDade, Eric , Klunk, William E. , Fox, Nick C. , Xiong, Chengjie , Hassenstab, Jason , Goate, Alison , Hanseeuw, Bernard , Lee, Jae‐Hong , Jucker, Mathias , Allegri, Ricardo , Benzinger, Tammie L.S. , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Gordon, Brian A. , Martins, Ralph N. , Noble, James M. , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Karch, Celeste M. , Johnson, Keith A. , Bateman, Randall J. , Sperling, Reisa Anne , DIAN

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.050864 Get It

AbstractBackgroundThough pathogenic variations in PSEN1 leading to Autosomal Dominant Alzheimer's disease (ADAD) are all highly penetrant, there is substantial inter‐individual variability in the rates of cognitive decline and biomarker change observed in ADAD. We hypothesized that this inter‐individual variability may be associated with the location of the pathogenic variant within PSEN1. We tested this hypothesis using biomarker and cognitive data from the Dominantly Inherited Alzheimer Network (DIAN) observational study.MethodPSEN1 pathogenic variant carriers [grouped based on whether their ADAD genotype affected transmembrane (PSEN1 TM; N = 125) or cytoplasmic (PSEN1 CY; N = 62) domains] and non‐carriers [NC; N = 176] enrolled in DIAN underwent clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF). Linear mixed effects models with a restricted cubic spline were used to determine cross‐sectional differences in clinical and biomarker measures between NC, PSEN1 TM, and PSEN1 CY groups, across the disease course (estimated years to symptom onset; EYO).ResultBackground characteristics are reported in Table 1. PSEN1 CY and PSEN1 TM groups had elevated β‐amyloid (PiB‐PET) and phosphorylated‐tau levels (CSF pTauT181) compared to NC, but these biomarker measures were not different between PSEN1 TM and CY groups (Figure 1a‐b). Additionally, the PSEN1 TM group had decreased glucose metabolism compared to NC but was similar to the PSEN1 CY group (Figure 1c). However, we observed that PSEN1 TM carriers had significantly smaller hippocampal volume, greater lateral ventricle volume, and greater cognitive impairment (Figure 1d‐f) across EYO as compared to PSEN1 CY carriers.ConclusionDespite similar β‐amyloid PET and CSF pTauT181 levels across EYO, individuals with pathogenic variants affecting transmembrane domains in PSEN1 may have more rapid progression of disease as measured by cognitive function and neurodegeneration as compared to those with variants affecting cytoplasmic domains. These results have implications both for understanding the heterogeneity in ongoing ADAD clinical trials and for better understanding the pathobiology of ADAD.
Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease
Barthélemy, Nicolas R. , Goate, Alison , Hassenstab, Jason , Fagan, Anne M. , Xiong, Chengjie , Cruchaga, Carlos , Farlow, Martin R. , Graff‐Radford, Neill R. , Laske, Christoph , Masters, Colin L. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Network, Dominantly Inherited Alzheimer, Chhatwal, Jasmeer P. , Fitzpatrick, Colleen , Bodge, Courtney, Cruz, Chrismary De La, Mejia, Arlene, Neimeyer, Katie, Gardener, Samantha L. , Taddei, Kevin , Ping, Lingyan, Seyfried, Nick , Gräber‐Sultan, Susanne, Häsler, Lisa M., Käser, Stephan, Kuder-Buletta, Elke, Preische, Oliver, Diffenbacher, Anna, Igor, Yakushev, Levin, Johannes, Vöglein, Jonathan , Obermüller, Ulricke, Esposito, Bianca, Goate, Alison, Buck, Jill , Farlow, Marty, Chrem, Patricio, Egido, Noelia , Haass, Christian , Nuscher, Brigitte , Day, Gregory S. , Graham, Morgan, Stephens, Sochenda, Bechara, Jacob , Araki, Aki, Ishii, Kenji , Senda, Michio , Ihara, Ryoko , Nagamatsu, Akemi, Fox, Nick C. , Mummery, Cath, Goldberg, Sarah B. , Ikonomović, Snežana, Mountz, James M. , Nadkarni, Neelesh K. , Patira, Riddhi , Smith, Lori, Snitz, Beth E. , Thompson, Sarah , Weamer, Elise A., Mason, Neal Scott, Chui, Helena, Ringman, John M. , Adams, Sarah , Brandon, Susan E. , Buckles, Virginia, Cash, Lisa, Chen, Charlie, Chua, Jasmin, Cruchaga, Carlos, Denner, Darcy, Dincer, Aylin , Donahue, Tamara, Feldman, Becca , Franklin, Erin , Friedrichsen, Nelly, Gonzalez, Alyssa, Gray, Julia, Gremminger, Emily, Groves, Alex, Hassenstab, Jason, Hellm, Cortaiga, Herries, Elizabeth, Hoechst-Swisher, Laura, Hornbeck, Russ C. , Jerome, Gina, Keefe, Sarah , Koudelis, Deb, Martinez, Rita, Mawuenyega, Kwasi G., McCullough, Austin , McDade, Eric, Norton, Joanne, Perrin, Richard J. , Shady, Kristine, Sigurdson, Wendy, Xu, Jinbin , Cruchaga, Carlos , Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Lim, Yen Ying , Maruff, Paul , Sato, Chihiro , Benzinger, Tammie L.S. , Xiong, Chengjie , Schofield, Peter R. , McDade, Eric , Network, Dominantly Inherited Alzheimer, Fitzpatrick, Colleen, Goldman, Jill , Noble, James M. , Martins, Ralph N. , Sohrabi, Hamid R. , Carter, Kathleen, Duong, Duc M , Johnson, Erik C. B. , Levey, Allan I. , Ping, Lingyan, Hofmann, Anna, Jucker, Mathias , Levin, Johannes, Goate, Alison, Renton, Alan , Brosch, Jared R. , Buck, Jill, Ghetti, Bernardino , Allegri, Ricardo , Morenas‐Rodríguez, Estrella , Jack, Clifford R. , Brooks, William S. , Ikeuchi, Takeshi , Kasuga, Kensaku , Fujii, Hisako , Shimada, Hiroyuki , Niimi, Yoshiki , Douglas, Jane, Grilo, Miguel, O’Connor, Antoinette , Koeppe, Robert A. , Berman, Sarah , Klunk, William E. , López, Oscar L. , Brandon, Susan, Cruchaga, Carlos, Feldman, Becca, Flores, Shaney , Gordon, Brian A. , Hassenstab, Jason, Holtzman, David M. , Karch, Celeste M. , Li, Yan , Marsh, Jacob, McDade, Eric, Smith, Jennifer A. , Wang, Peter , Wang, Qing , Xu, Xiong

Mayo Clinic

JAMA Neurology | January 31, 2022 | Volume: 79 | Issue: 3 | Pages: 261

10.1001/jamaneurol.2021.5181 | PMID 35099506 Get It

Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection part 2: Psychological functioning
Whiteside, Douglas M. , Naini, Savana M. , Basso, Michael R. , Waldron, Eric J. , Holker, Erin , Porter, James N., Niskanen, Natalie, Melnik, Tanya E., Whiteside, Douglas , Taylor, Sarah E.

Mayo Clinic

The Clinical Neuropsychologist | January 31, 2022 | Volume: 36 | Issue: 4 | Pages: 829-847

10.1080/13854046.2022.2030411 | PMID 35098861 Get It

Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes
O’Malley, Grenye , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Lum, John W. , Brown, Sue A. , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Ekhlaspour, Laya , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Kudva, Yogish C. , Laffel, Lori M , Pinsker, Jordan E , Lum, John , Forlenza, Gregory P , Levy, Carol J. , Kovatchev, Boris , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Alonso, G. Todd , Messer, Laurel H , Buckingham, Bruce A. , Doyle, Francis J. , Beck, Roy W. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | January 31, 2022 | Volume: 24 | Issue: 5 | Pages: 357-361

10.1089/dia.2021.0431 | PMID 35099294 Get It

Objective: To analyze insulin delivery and glycemic metrics throughout the menstrual cycle for women with type 1 diabetes using closed loop control (CLC) insulin delivery. Methods: Menstruating women using a CLC system in a clinical trial were invited to record their menstrual cycles through a cycle-tracking application. Sixteen participants provided data for this secondary analysis over three or more complete cycles. Insulin delivery and continuous glucose monitoring (CGM) data were analyzed in relation to reported cycle phases. Results: Insulin delivery and CGM metrics remained consistent during cycle phases. Intraparticipant variability of CGM metrics and weight-based insulin delivery did not change through cycle phases. Conclusions: For this sample of menstruating women with type 1 diabetes using a CLC system, insulin delivery and glycemic metrics remained stable throughout menstrual cycle phases. Additional studies in this population are needed, particularly among women who report variable glycemic control during their cycles. Trial Registration: NCT03591354.
Primary Effusion Lymphoma: A Clinicopathologic Perspective
Gathers, Diamone, Galloway, Emily A., Kelemen, Katalin, Gathers, Diamone A , Gibson, Sarah E. , Rosenthal, Allison , Muñoz, Javier

Mayo Clinic

Cancers | January 31, 2022 | Volume: 14 | Issue: 3 | Pages: 722

10.3390/cancers14030722 | PMID 35158997 Get It

Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma that usually localizes to serous body cavities to subsequently form effusions in the absence of a discrete mass. Although some tumors can develop in extracavitary locations, the areas most often affected include the peritoneum, pleural space, and the pericardium. PEL is associated with the presence of human herpesvirus 8 (HHV8), also called the Kaposi sarcoma-associated herpesvirus (KSHV), with some variability in transformation potential suggested by frequent coinfection with the Epstein-Barr virus (EBV) (~80%), although the nature of the oncogenesis is unclear. Most patients suffering with this disease are to some degree immunocompromised (e.g., Human immunodeficiency virus (HIV) infection or post-solid organ transplantation) and, even with aggressive treatment, prognosis remains poor. There is no definitive guideline for the treatment of PEL, although CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone) are frequently prescribed and, given the rarity of this disease, therapeutic focus is being redirected to personalized and targeted approaches in the experimental realm. Current clinical trials include the combination of lenalidomide and rituximab into the EPOCH regimen and the treatment of individuals with relapsed/refractory EBV-associated disease with tabelecleucel.
Meeting Report: Aging Research and Drug Discovery
Meron, Esther, Thaysen, Maria, Antebi, Adam , Barzilai, Nir , Birkisdóttir, María B. , Bruening, Jens, Brunet, Anne , Cai, Shi‐Qing , Chen, Brian H. , Ermolaeva, Maria , Ewald, Collin Y. , Ferrucci, Luigi , Fortney, Kristen , Freund, Adam , Georgievskaya, Anastasia , Gladyshev, Vadim N. , Golato, Tyler, Hoejimakers, Jan, Houtkooper, Riekelt H. , Jaksch, Frank, Janssens, Georges E. , Jensen, Martin Borch , Kirkland, James L. , Kjær, Michael , Lee, Kai-Fu, Lemaı̂tre, Jean-Marc , Liaskos, David, Longo, Valter D. , Lu, Yuxuan , MacArthur, Michael R. , Maier, Andrea B. , Manakanatas, Christina, Mitchell, Sarah J. , Moskalev, Alexey , Niedernhofer, Laura J. , Ozerov, Ivan V. , Peyer, James , Radenković, Dina , Rattan, Suresh I. S. , Riedel, Christian G. , Schumacher, Björn , Smith, Ryan , Suh, Yousin , Trapp, Alexandre , Trendelenburg, Anne‐Ulrike, Valenzano, Dario Riccardo , Verburgh, Kris, Zhavoronkov, Alex , Niedernhofer, Laura J , Ferrucci, Luigi , Gladyshev, Vadim N , Thaysen, Maria , Angeli, Suzanne , Baur, Joseph A. , Bekker‐Jensen, Simon , Bischof, Evelyne Y. , Bruening, Jens, Buchwalter, Abigail L. , Cabreiro, Filipe , Florian, Maria Carolina , Glass, David J. , Golato, Tyler, Gorbunova, Vera , Jäger, Sibylle , Kaeberlein, Matt R. , Karsenty, Gérard , Keizer, Peter L.J. de , Kennedy, Brian Keith , Kroemer, Guido , Liaskos, David, Partridge, Linda , Passegue, Emmanuelle A. , Petr, Michael Angelo , Rando, Thomas A. , Rudolph, K. Lenhard , Ai, Ruixue , Serrano, Manuel , Sinclair, David , Suh, Yousin , Taub, Pam R. , Verdin, Eric , Vijg, Jan , Westendorp, Rudi G. J. , Zonari, Alessandra Arcoverde Cavalcanti , Bakula, Daniela , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | January 28, 2022 | Volume: 14 | Issue: 2 | Pages: 530-543

10.18632/aging.203859 Get It